alalevonadifloxacin (Wockhardt)

Alalevonadifloxacin (WCK 2349) is an oral, broad-spectrum antibiotic belonging to the benzoquinolizine subclass of fluoroquinolones, developed by Wockhardt. It is a mesylate salt of an alanine ester prodrug of levonadifloxacin (WCK 771), designed with greater than 90% oral bioavailability to facilitate oral step-down therapy or primary oral treatment. The drug exerts its antibacterial effect by dual inhibition of bacterial DNA gyrase and topoisomerase IV, demonstrating potent activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), quinolone-resistant S. aureus, and vancomycin-non-susceptible strains. It has been approved in India for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot infections and concurrent bacteremia. Alalevonadifloxacin has also received Qualified Infectious Disease Product (QIDP) status from the US FDA and is noted for its lack of typical fluoroquinolone-associated adverse effects such as phototoxicity and QT interval prolongation.

Brand names

EMROK O

Other names

alalevonadifloxacin mesylate